David A. Braun, MD, PhD, shares his takeaways from the network meta-analysis on lenvatinib plus pembrolizumab in advanced RCC, and Martin H. Voss, MD, discusses outcomes with cabozantinib following frontline lenvatinib plus pembrolizumab.
Retrospective Data Show Metastasectomy Plus Nephrectomy Improves Survival in Non–ccRCC
Merkow and Connell Highlight Considerations for HAI Pump Use in CRC
ADCs and Immunotherapy Broaden the Bladder Cancer Treatment Paradigm
Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR Tumors
Mainstreaming of Genetic Testing Is Tied to Increased Testing Rates in Ovarian Cancer
State of the Science Summit - Hematologic Malignancies: Chaired by Minoo Battiwalla, MD, MS
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC